ReachRxResearch
Home
Research
Sign Up
No evidence of hypercoagulability, altered fibrinolysis, or increased fibrin(ogen) microaggregates in never‐hospitalized long COVID
Back to Research Hub
  1. Home
  2. Research Hub
  3. No evidence of hypercoagulability, alter…

No evidence of hypercoagulability, altered fibrinolysis, or increased fibrin(ogen) microaggregates in never‐hospitalized long COVID

HemaSphere·October 19Open Access
HematologyPractice changingLong COVIDPost-COVID-19 ConditionProspective Observational Cohort StudyAnticoagulantPlasma ExchangeAdultXareltoRivaroxaban

Summary

View source

What was studied

This study tested whether never-hospitalized adults with specialist-confirmed long COVID (LC) — breathless (BLC, n=80) or non-breathless (NBLC, n=37) — had evidence of hypercoagulability, impaired fibrinolysis, abnormal fibrin architecture, or increased fibrin(ogen) microaggregates compared to fully recovered COVID-19 controls (n=34), using a broad panel of hemostasis biomarkers and quantitative confocal fibrin analysis.

Key findings

No significant differences were found between LC groups and controls across all prothrombotic markers (D-dimer, fibrinogen, VWF, thrombomodulin, P-selectin, PAI-1, 50% clot lysis time, NETosis markers), fibrin fiber density (47.9 vs. 43.6 vs. 38.0 fibers/100 µm; P=0.22), or fibrin(ogen) microaggregate number and area; no meaningful correlations were found with breathlessness, fatigue, or pulmonary perfusion/gas transfer metrics.

Study limitations

Single time-point sampling; subgroup-only fibrin microaggregate analysis (n=55); population was largely White/Caucasian; findings are not generalizable to hospitalized LC patients, who represent a different severity spectrum.

Clinical implications

Antithrombotic therapy (e.g., anticoagulants, plasma exchange) is not supported for never-hospitalized long COVID in the absence of a separate recognized thrombotic indication. Clinicians should not prescribe these treatments outside clinical trials based on the 'microclot' hypothesis.

Related Questions

Explore related topics

What is the evidence for antithrombotic therapy in long COVID management?Do fibrin microaggregates or 'microclots' cause symptoms in post-COVID syndrome?What biomarkers distinguish hospitalized versus never-hospitalized long COVID patients?

Publication Details

Year
2026
Journal
HemaSphere
Sample Size
n=151
Source
View article
Keep scrolling
More content below.
Up Next